Abstract
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Current Pharmaceutical Biotechnology
Title:Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Volume: 16 Issue: 5
Author(s): Tessalia D.L. Saraiva, Katia Morais, Vanessa B. Pereira, Marcela de Azevedo, Clarissa S. Rocha, Camila C. Prosperi, Ana C. Gomes-Santos, Luis Bermudez-Humaran, Ana M.C. Faria, Herve M. Blottiere, Philippe Langella, Anderson Miyoshi, Alejandra de Moreno de LeBlanc, Jean G. LeBlanc and Vasco Azevedo
Affiliation:
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Abstract: Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Export Options
About this article
Cite this article as:
Saraiva D.L. Tessalia, Morais Katia, Pereira B. Vanessa, Azevedo de Marcela, Rocha S. Clarissa, Prosperi C. Camila, Gomes-Santos C. Ana, Bermudez-Humaran Luis, Faria M.C. Ana, Blottiere M. Herve, Langella Philippe, Miyoshi Anderson, LeBlanc de Moreno de Alejandra, LeBlanc G. Jean and Azevedo Vasco, Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model, Current Pharmaceutical Biotechnology 2015; 16 (5) . https://dx.doi.org/10.2174/1389201015666141113123502
DOI https://dx.doi.org/10.2174/1389201015666141113123502 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Targets of Curcumin
Current Drug Targets Current Advances in Food Science & Health Promotion (Part I)
Current Pharmaceutical Biotechnology Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Current Pharmaceutical Design Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Therapeutic Implications of mTOR Inhibitors in the Treatment of Gastric Cancer
Current Cancer Drug Targets Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Current Cancer Drug Targets Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition
Current Drug Targets The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry